Milademetan
- Generic Name
- Milademetan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34Cl2FN5O4
- CAS Number
- 1398568-47-2
- Unique Ingredient Identifier
- R3I80TLN7S
- Background
Milademetan is under investigation in clinical trial NCT02319369 (Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)).
- Associated Conditions
- -
- Associated Therapies
- -
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Rain Oncology Inc
- Registration Number
- NCT06090318
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 1
- Registration Number
- NCT05932667
- Locations
- 🇫🇷
Institut Du Cancer Montpellier, Montpellier, France
🇫🇷Institut Curie, Saint-Cloud, France
🇫🇷Centre Eugene Marquis, Rennes, France
A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 6
- Registration Number
- NCT05758818
- Locations
- 🇦🇺
Nucleus Network Melbourne, Melbourne, Victoria, Australia
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03671564
- Locations
- 🇯🇵
Kyusyu University Hospital, Fukuoka, Japan
🇯🇵Tenri Hospital, Nara, Japan
🇯🇵Gifu Municipal Hospital, Gifu, Japan
Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 36
- Registration Number
- NCT03614455
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 10
- Registration Number
- NCT03552029
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Duke University Cancer Center, Durham, North Carolina, United States
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 74
- Registration Number
- NCT02319369
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of California San Francisco Medical Center, San Francisco, California, United States
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States
A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 107
- Registration Number
- NCT01877382
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Columbia University College of Physicians and Surgeons, New York, New York, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.